Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
Dig Dis Sci ; 43(9): 1946-50, 1998 Sep.
Article in English | MEDLINE | ID: mdl-9753256

ABSTRACT

The differential urinary excretion of orally administered lactulose and mannitol is used to evaluate intestinal permeability. This test usually involves a 5- to 6-hr urine collection. We hypothesized that a shorter collection time would give an equivalent result. Forty-three patients with a variety of gastrointestinal symptoms and diagnoses (group 1) and 42 patients with Crohn's disease (group 2) had a standard lactulose/mannitol permeability test. The lactulose and mannitol urinary excretion was calculated using the first urine (group 1) or the 1-hr and 2-hr urine (group 2) and was compared to the values calculated from the routine 5- or 6-hr collection. Lactulose excretion kinetics, expressed as the percent of the total urinary excretion within a given time period, were as follows: 21% in first hour (group 2), 29% in second hour (group 2), and 46% in first 2.5 hr (group 1). Mannitol urinary excretion kinetics were 16%, 31%, and 44%, respectively. The lactulose/mannitol ratio based on a standard urine collection correlated well with the ratio based on just the first urine produced by the patient (R2 = 0.94; P < 0.001; group 1) and the 2-hr urine (R2 = 0.464; P < 0.001; group 2). Future use of the lactulose/mannitol ratio to assess intestinal permeability may be able to be simplified by shortening the urine collection time.


Subject(s)
Intestinal Absorption , Intestinal Mucosa/physiopathology , Intestine, Small/physiopathology , Lactulose/urine , Mannitol/urine , Specimen Handling/methods , Administration, Oral , Adult , Aged , Female , Humans , Lactulose/administration & dosage , Male , Mannitol/administration & dosage , Middle Aged , Time Factors
2.
Saudi J Gastroenterol ; 2(2): 57-62, 1996 May.
Article in English | MEDLINE | ID: mdl-19864828

ABSTRACT

Esophageal endoprostheses are very useful in management of patients with esophageal cancer and are the primary therapy for patients with esophagorespiratory fistula. In addition, patients with tumors, poorly responsive to dilatation or other therapies, will have long-lasting symptomatic relief when an endoprosthesis is placed. The available prostheses are discussed, as well as the methods of insertion and the relative merits of each. The self- expanding metal stents may have advantages over plastic stents.

SELECTION OF CITATIONS
SEARCH DETAIL
...